Table of Contents :
• Stock Rating & Target Price
• Investment Thesis
• Fundamental Models Used
• Company Description
• Corporate Timeline
• Key Metrics (KPI ) and Recently Reported Earnings Review
• Business Highlights, Strategic Announcements & Outlook
• Quarter-over-Quarter (Q-o-Q) and Year-over-Year (Y-o-Y) Growth Analysis
• Key Catalysts Driving Growth
• Historical Financial Statement Analysis & CAGR Trends
• Quarterly Key Financial Ratios and Performance Metrics
• Annual Financial Performance Analysis: Horizontal and Vertical Financial Analysis, Trends
• Financial Forecasts
• Annual Forecasts: Income Statement
• Annual Forecasts: Cash Flow Statements
• Net Debt Levels
• A Closer Look at DCF: Our Assumptions and Methodology
• Terminal Value Calculation
• Target Price Analysis
• Valuation Multiples
• Supplementary Valuation Analysis: Multiples Approach
• Scenario/Sensitivity Analysis – Base Case , Bull Case ,Bear Case
• Holistic Peer Review & Trading Comps: Financial Data, Operational Metrics, and Valuation Multiples
• Implied Price Per Share
• Ownership Activity/ Insider Trades
• Ownership Summary
• An analysis of ESG Risk Rating
• Key Professionals
• Key Board Members
• Key Risks Considerations
• Analyst Ratings
• Analyst Industry Views
• Disclosures
Zimmer Biomet Holdings Inc’s (ZBH) New Product Surge Is Real—But Can It Fix the Knee Problem Before Tariffs Bite?
Zimmer Biomet’s Q1FY25 print reflects steady progress on transformation priorities—innovation, commercial recalibration, and portfolio diversification—though operational torque remains weighted to H2. Constant currency sales growth of 2.3% (~3.5–4% normalized) trends toward the low end of the 3–5% organic guide, with Paragon 28 adding 270bps to reported growth and enhancing the higher-growth S.E.T. portfolio. U.S. Hip outperformance (+3.7%) validates product cycle execution, while U.S. Knee remains a drag (+0.2%), with management banking on H2 ramp from cementless adoption and ROSA integration. Gross and operating margin compressed 90bps/160bps Y/Y as tariffs, FX, and launch costs weighed, though EPS guidance was revised to $7.90–8.10 with full offset via FX tailwinds and cost flex. FCF guidance reset to $750–850M reflects integration and tariff headwinds but is manageable within deleveraging goals. Commercial model shift toward ASCs (>20% U.S. sales) and underappreciated enabling technologies (ROSA Knee 1.5, iodine-treated implants) offer incremental growth levers. Paragon 28 integration is progressing well, supporting future accretive adjacency pursuits. However, knee franchise momentum and tariff exposure remain core watchpoints; Q4 will bear >50% of FY tariff impact. Can Zimmer Biomet achieve a sustained inflection in its knee franchise before tariff headwinds and margin dilution test investor confidence deeper into FY26?
